Baidu
map

Chest:中国肺癌死亡率的空间和时间趋势

2019-08-15 xing.T MedSci原创

由此可见,亚组人群中LCMR的时空趋势差异凸显了对潜在驱动因素进行调查的必要性,尤其是对中国东部、南部和西南部的驱动因素。这些发现可能有助于卫生部分针对最需要的人群进行干预,以减轻中国的肺癌负担。

近日,呼吸领域权威杂志chest上发表了一篇研究文章,该研究旨在确定中国人群(即地区、年龄和性别)亚组肺癌死亡率(LCMR)的时空变化趋势。

研究人员从中国国家死亡监测中心提取了2006年至2015年的LCMR数据。连接点回归和季节性分解用于评估时间变化趋势。地理信息系统和空间克里金插值用于评估空间趋势。 

从2009年到2015年,30至49岁男性的LCMR显著下降(年变化百分比:-2.7%,P<0.05),但70岁以上的男性、东部50岁以上的女性、南部50至69岁的人群以及西南部​​大多数人群中LCMR持续上升。在省会城市中,沉阳、长沙和呼和浩特的男性年平均LCMR分别为30至49岁、50至69岁和70岁以上,而在所有年龄段的女性中,哈尔滨的平均LCMR最高。十年来,随着经度或纬度增加1°(ORs范围从0.93(95%CI 0.90-0.95)到0.97(95%CI为 0.95-0.99)),30至69岁男性和女性的LCMR增加的几率下降3%至7%。

由此可见,亚组人群中LCMR的时空趋势差异凸显了对潜在驱动因素进行调查的必要性,尤其是对中国东部、南部和西南部的驱动因素。这些发现可能有助于卫生部分针对最需要的人群进行干预,以减轻中国的肺癌负担。 

原始出处:

Ning Wang,et al.Lung cancer mortality in China: spatial and temporal trends among subpopulations.chest.2019. https://doi.org/10.1016/j.chest.2019.07.023

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2055422, encodeId=89f82055422ec, content=<a href='/topic/show?id=19b88223132' target=_blank style='color:#2F92EE;'>#肺癌死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82231, encryptionId=19b88223132, topicName=肺癌死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 03 14:49:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051424, encodeId=53102051424ee, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 29 12:49:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951606, encodeId=7ab9195160609, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Aug 17 04:49:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929577, encodeId=ee6319295e7e9, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Apr 08 04:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371479, encodeId=fd4a3e147977, content=变化的数据,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Aug 19 06:58:11 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371303, encodeId=6e7b3e130360, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 15 14:20:08 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2055422, encodeId=89f82055422ec, content=<a href='/topic/show?id=19b88223132' target=_blank style='color:#2F92EE;'>#肺癌死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82231, encryptionId=19b88223132, topicName=肺癌死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 03 14:49:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051424, encodeId=53102051424ee, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 29 12:49:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951606, encodeId=7ab9195160609, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Aug 17 04:49:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929577, encodeId=ee6319295e7e9, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Apr 08 04:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371479, encodeId=fd4a3e147977, content=变化的数据,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Aug 19 06:58:11 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371303, encodeId=6e7b3e130360, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 15 14:20:08 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2055422, encodeId=89f82055422ec, content=<a href='/topic/show?id=19b88223132' target=_blank style='color:#2F92EE;'>#肺癌死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82231, encryptionId=19b88223132, topicName=肺癌死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 03 14:49:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051424, encodeId=53102051424ee, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 29 12:49:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951606, encodeId=7ab9195160609, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Aug 17 04:49:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929577, encodeId=ee6319295e7e9, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Apr 08 04:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371479, encodeId=fd4a3e147977, content=变化的数据,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Aug 19 06:58:11 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371303, encodeId=6e7b3e130360, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 15 14:20:08 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2055422, encodeId=89f82055422ec, content=<a href='/topic/show?id=19b88223132' target=_blank style='color:#2F92EE;'>#肺癌死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82231, encryptionId=19b88223132, topicName=肺癌死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 03 14:49:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051424, encodeId=53102051424ee, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 29 12:49:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951606, encodeId=7ab9195160609, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Aug 17 04:49:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929577, encodeId=ee6319295e7e9, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Apr 08 04:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371479, encodeId=fd4a3e147977, content=变化的数据,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Aug 19 06:58:11 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371303, encodeId=6e7b3e130360, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 15 14:20:08 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
    2020-04-08 Smile2680
  5. [GetPortalCommentsPageByObjectIdResponse(id=2055422, encodeId=89f82055422ec, content=<a href='/topic/show?id=19b88223132' target=_blank style='color:#2F92EE;'>#肺癌死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82231, encryptionId=19b88223132, topicName=肺癌死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 03 14:49:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051424, encodeId=53102051424ee, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 29 12:49:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951606, encodeId=7ab9195160609, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Aug 17 04:49:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929577, encodeId=ee6319295e7e9, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Apr 08 04:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371479, encodeId=fd4a3e147977, content=变化的数据,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Aug 19 06:58:11 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371303, encodeId=6e7b3e130360, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 15 14:20:08 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
    2019-08-19 Dr Z

    变化的数据,学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2055422, encodeId=89f82055422ec, content=<a href='/topic/show?id=19b88223132' target=_blank style='color:#2F92EE;'>#肺癌死亡率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82231, encryptionId=19b88223132, topicName=肺癌死亡率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f49517, createdName=xinmeili, createdTime=Fri Apr 03 14:49:00 CST 2020, time=2020-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2051424, encodeId=53102051424ee, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Sun Dec 29 12:49:00 CST 2019, time=2019-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1951606, encodeId=7ab9195160609, content=<a href='/topic/show?id=53a5595e1dc' target=_blank style='color:#2F92EE;'>#时间趋势#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59571, encryptionId=53a5595e1dc, topicName=时间趋势)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=917c196, createdName=sjzlzc007, createdTime=Sat Aug 17 04:49:00 CST 2019, time=2019-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1929577, encodeId=ee6319295e7e9, content=<a href='/topic/show?id=9e604625ab' target=_blank style='color:#2F92EE;'>#Chest#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4625, encryptionId=9e604625ab, topicName=Chest)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c48a270, createdName=Smile2680, createdTime=Wed Apr 08 04:49:00 CST 2020, time=2020-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371479, encodeId=fd4a3e147977, content=变化的数据,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/08/03/0e492dda8bcc1f98474b74c2863aca87.jpg, createdBy=068d2446376, createdName=Dr Z, createdTime=Mon Aug 19 06:58:11 CST 2019, time=2019-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=371303, encodeId=6e7b3e130360, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Thu Aug 15 14:20:08 CST 2019, time=2019-08-15, status=1, ipAttribution=)]
    2019-08-15 phoebeyan520

    学习了

    0

相关资讯

肺癌丨精准医疗,肺鳞癌的诊疗

从目前的临床实践应用来看,肺癌靶向治疗[EGFR(18、19、20、21、遗珠、胞外域、复合突变)、ALK、ROS1、RET、MET、HER2、KRAS、BRAF、NTRK、NRG1等]、抗血管生成治疗,免疫治疗(免疫治疗生物标志物、超进展、假性进展,耐药机制),化疗,鳞癌诊疗,小细胞癌诊疗,非小细胞肺癌脑转移,非小细胞肺癌术后辅助治疗(点击阅读)等这几大主题值得探讨,今天我们分享肺鳞癌诊疗。

罕见中央型肺癌并自发性肺扭转一例

患者男,54岁。胸痛、憋闷数周,咳痰伴少许血丝,平日吸烟较重。临床以慢性支气管炎治疗,效果不佳,遂来本院就诊。临床查体未见明显异常。实验室检查阴性。

免疫治疗将会贯穿肺癌的全程治疗

由上海市抗癌协会、上海医药行业协会联合主办,复旦大学附属肿瘤医院承办,上海市抗癌协会肺癌分子靶向与免疫治疗专业委员会、上海市抗癌协会胸部肿瘤专业委员会和中国研究型医院学会分子肿瘤与免疫治疗专委会协办的“第五届胸部肿瘤浦江论坛” 在上海隆重举行。会议期间,有幸采访到浙江省肿瘤医院的范云教授,就Ⅲ期非小细胞肺癌(NSCLC)的诊疗现状和免疫治疗前移做一专访。

中国肺癌临床研究的趋势:免疫治疗不能只关注PD-1/PD-L1

第九届中国肿瘤学临床试验发展论坛暨GACT/CTONG 2019年度会议在羊城广州隆重召开。会议前夕,【肿瘤资讯】对大会主席、广东省人民医院的吴一龙教授进行专访,介绍中国肺癌领域临床试验的发展变化特点及发展趋势。

中国肺癌临床研究趋势:免疫治疗不能只关注PD-1/PD-L1

2019年8月2-3日,第九届中国肿瘤学临床试验发展论坛暨GACT/CTONG 2019年度会议在羊城广州隆重召开。会议前夕,对大会主席、广东省人民医院的吴一龙教授进行专访,介绍中国肺癌领域临床试验的发展变化特点及发展趋势。

Chest:间质性肺部异常与肺癌风险

由此可见,无症状间质性肺部异常是肺癌的独立危险因素,可纳入风险评分模型中。

Baidu
map
Baidu
map
Baidu
map